Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany.
Amelie WickmannMelina Sophie KurteJulia JeckLuisa CamachoDennis KlinkhammerFlorian KronRobert DenglerPublished in: Cost effectiveness and resource allocation : C/E (2024)
Vinorelbine is most cost-effective, followed by SG. Health-economic evaluations support decision-makers to assess treatment options within one indication area. In Germany, the efficiency frontier can provide decision support for the pricing of innovative interventions. Results of our analysis may thus guide reimbursement determination.
Keyphrases
- public health
- healthcare
- squamous cell carcinoma
- small cell lung cancer
- mental health
- physical activity
- health information
- randomized controlled trial
- clinical trial
- radiation therapy
- decision making
- molecularly imprinted
- risk assessment
- stem cells
- mesenchymal stem cells
- bone marrow
- mass spectrometry
- health promotion
- social media
- open label
- locally advanced